Techniques anesthésiques locorégionales et qualité de vie en soins palliatifs - TALVISOP

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2009-016701-42-FR

Enrollment

Registered

2009-12-17

Start date

2010-01-22

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

palliative care Cancer pain MedDRA version: 12.1 Level: LLT Classification code 10059513 Term: Palliative care MedDRA version: 12.1 Level: LLT Classification code 10058019 Term: Cancer pain

Interventions

Trade Name: MORPHINE (CHLORHYDRATE) Pharmaceutical Form: Injection* CAS Number: 52-26-6 Other descriptive name: MORPHINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Co

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patient = 18 years-old, male or female, - Patient with untreatable cancer - Patient hospitalized in a palliative care unit, with a life expectancy = 1 week - Pain unresponsive to conventional treatments - Signed informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - Age less than 18 years - Patients with pain other than cancer pain - Patient’s refusal - Coagulation disorders - Local infection - Known hypersensitivity to local analgesics - Inefficacy of the injection test - Incapable adult patient - Contraindication for analgesics

Design outcomes

Primary

Measure	Time frame
Main Objective: Evaluate the improvement of the quality of life for patients using the 15th item of the EORTC QLQ-C15-PAL questionnary, a week after the introduction of an analgesia;Secondary Objective: - Evaluate the improvement of the various dimensions of quality of life objectified by the questionnaire EORTC QLQ-C15-PAL, a week after the introduction of analgesia. - Assessing the Quality of life for patients using the 15th item of the EORTC QLQ-C15-PAL questionnary, 48 h and one month after the introduction of an analgesia. - Evaluate , by VAS, the improvement of the painful condition of the patient 48 hours after the establishment of analgesia . - Evaluate reducing doses of conventional drug treatments orally or parenterally 1 weeks after the introduction of an analgesia.;Primary end point(s): To evaluate the change in patients global quality of life, assessed by the item 15 of the validated quality of life scale EORTC QLQ-C15 PAL. Evaluations will take place before the procedure of locoregional analgesia and 1 week after.	—

Measure

Time frame

Main Objective: Evaluate the improvement of the quality of life for patients using the 15th item of the EORTC QLQ-C15-PAL questionnary, a week after the introduction of an analgesia;Secondary Objective: - Evaluate the improvement of the various dimensions of quality of life objectified by the questionnaire EORTC QLQ-C15-PAL, a week after the introduction of analgesia. - Assessing the Quality of life for patients using the 15th item of the EORTC QLQ-C15-PAL questionnary, 48 h and one month after the introduction of an analgesia. - Evaluate , by VAS, the improvement of the painful condition of the patient 48 hours after the establishment of analgesia . - Evaluate reducing doses of conventional drug treatments orally or parenterally 1 weeks after the introduction of an analgesia.;Primary end point(s): To evaluate the change in patients global quality of life, assessed by the item 15 of the validated quality of life scale EORTC QLQ-C15 PAL. Evaluations will take place before the procedure of locoregional analgesia and 1 week after.

—

Countries

France

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026